

DAFTAR PUSTAKA

- Ajaero, O. C., Uneke, P. C., & Ajaero, N. U. (2021). *Effects of Cabergoline and Bromocriptine on Prolactin, Progesterone, Luteinizing and Follicle Stimulating Hormones in Hyperprolactinaemic Infertile Women in Orlu, Nigeria*. 5(5), 1633–1641.
- Akter, N., Kabir Qureshi, N., & Akter, T. (2018). Hyperprolactinemia: A Systematic Review of Diagnosis and Management. In *Delta Med Col J. Jul* (Vol. 6, Issue 2).
- Al-Husaynei, A. J., Mahmood, I. H., & Al-Jubori, Z. S. (2008). Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. *Middle East Fertility Society Journal*, 13(1), 33–38.
- Aldahmani, K., AlMalki, M., & Beshyah, S. (2020). A rational approach to the evaluation and management of patients with hyperprolactinemia. *Ibnosina Journal of Medicine and Biomedical Sciences*, 12(02), 90–97. https://doi.org/10.4103/ijmbs.ijmbs_38_20
- Ansari, M. S., & Almalki, M. H. (2016). Primary hypothyroidism with markedly high prolactin. *Frontiers in Endocrinology*, 7(APR), 1–5. <https://doi.org/10.3389/fendo.2016.00035>
- Appelman-Dijkstra, N. M., Kokshoorn, N. E., Dekkers, O. M., Neelis, K. J., Biermasz, N. R., Romijn, J. A., Smit, J. W. A., & Pereira, A. M. (2011). Pituitary dysfunction in adult patients after cranial radiotherapy: Systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, 96(8), 2330–2340. <https://doi.org/10.1210/jc.2011-0306>
- Bart, G., Schluger, J. H., Borg, L., Ho, A., Bidlack, J. M., & Kreek, M. J. (2005). Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity? *Neuropsychopharmacology*, 30(12), 2254–2262. <https://doi.org/10.1038/sj.npp.1300811>
- Bashir, H. E. AL, & Hamza, K. M. (2016). Comparison Between Bromocriptine and Cabergoline Drugs as a Treatment of Hyperprolactinemia Among Sudanese Infertile Amenorrhic Women. *Clinical Medicine Journal*, 2(1), 1–5. <http://www.aiscience.org/journal/cmjhttp://creativecommons.org/licenses/by-nc/4.0/>
- Ben-jonathan, N., & Hnasko, R. (2001). *Dopamine as a Prolactin (PRL) Inhibitor*. <https://academic.oup.com/edrv/article/22/6/724/2424026>
- Biagetti, B., & Simò, R. (2021). Molecular pathways in prolactinomas: Translational and therapeutic implications. In *International Journal of Molecular Sciences* (Vol. 22, Issue 20). MDPI. <https://doi.org/10.3390/ijms222011247>
- Binart, N. (2017). Prolactin. In *The Pituitary: Fourth Edition*. Elsevier Inc. <https://doi.org/10.1016/B978-0-12-804169-7.00005-2>
- Brannan, T., Martínez-Tica, J., Di Rocco, A., & Yahr, M. D. (1993). Low and high dose bromocriptine have different effects on striatal dopamine release: An in vivo study. *Journal of Neural Transmission - Parkinson's Disease and Dementia Section*, 6(2), 81–87. <https://doi.org/10.1007/BF02261001>

- Brown, T. E. R., Fernandes, P. A., Grant, L. J., Hutsul, J.-A., & Mccoshen, J. A. (2000). *Effect of Parity on Pituitary Prolactin Response to Metoclopramide and Domperidone: Implications for the Enhancement of Lactation*.
- Cao, Y., Wang, F., Liu, Z., & Jiao, B. (2016). Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery. *Experimental and Therapeutic Medicine*, 11(5), 1977–1982. <https://doi.org/10.3892/etm.2016.3122>
- Chanson, P., & Maiter, D. (2019). The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. *Clinical Endocrinology and Metabolism*, 33, 101290. <https://doi.org/10.1016/j.beem.2019.101290>
- Chowanadisai, W., Kelleher, S. L., & Lönnerdal, B. (2004). Maternal zinc deficiency raises plasma prolactin levels in lactating rats. *Journal of Nutrition*, 134(6), 1314–1319. <https://doi.org/10.1093/jn/134.6.1314>
- Corenblum, B. (2009). Bromocriptine Response in Pathological Hyperprolactinemia: A 34 Year Follow-Up of a Homogeneous Population of 827 Patients. *The Open Endocrinology Journal*, 3(1), 38–41. <https://doi.org/10.2174/1874216500903010038>
- Corenblum, B., & Taylor, P. J. (1983). Long-term follow-up of hyperprolactinemic women treated with bromocriptine. *Fertility and Sterility*, 40(5), 596–599. [https://doi.org/10.1016/S0015-0282\(16\)47415-7](https://doi.org/10.1016/S0015-0282(16)47415-7)
- Dabbous, Z., & Atkin, S. L. (2018). Hyperprolactinaemia in male infertility: Clinical case scenarios. *Arab Journal of Urology*, 16(1), 44–52. <https://doi.org/10.1016/j.aju.2017.10.002>
- Depkes RI. (2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/813/2019 tentang Formularium Nasional. In Departemen Kesehatan Republik Indonesia. In *Departemen Kesehatan Republik Indonesia*.
- Depkes RI. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/397/2020 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tumor Otak. In *Departemen Kesehatan Republik Indonesia*. <https://www.e-ir.info/2018/01/14/securitisation-theory-an-introduction/>
- Djursing, H., Hagen, C., Moller, J., & Christiansen, C. (1981). Short-and long-term fluctuations in plasma prolactin concentration in normal subjects. *Acta Endocrinologica*, 97, 1–6.
- Gasco, V., & Grottoli, S. (2018). Physiopathology, Diagnosis, and Treatment of Hyperprolactinemia. In *Endocrinology (Switzerland)*. https://doi.org/10.1007/978-3-319-38681-2_15-1
- Grant, P. (2011). *Bromocriptine*. *Practical Diabetes International* (Vol. 28, Issue 6). <https://doi.org/10.1002/pdi.1614>
- Gupta, S., Lakshmanan, D. A. M., Khastgir, U., & Nair, R. (2017). Management of antipsychotic-induced hyperprolactinaemia. *BJPsych Advances*, 23(4), 278–286. <https://doi.org/10.1192/apt.bp.115.014928>
- Hine, K., Harrop, J., Hopton, M., Holmes, G., & Matthews, H. (1984). The effects of ranitidine on pituitary-thyroid function. *British Journal of Clinical Pharmacology*, 18(4), 608–611. <https://doi.org/10.1111/j.1365->

2125.1984.tb02512.x

- Ishida, M., Mitsui, T., Yamakawa, K., Sugiyama, N., Takahashi, W., Shimura, H., Endo, T., Kobayashi, T., & Arita, J. (2007). Involvement of cAMP response element-binding protein in the regulation of cell proliferation and the prolactin promoter of lactotrophs in primary culture. *American Journal of Physiology - Endocrinology and Metabolism*, 293(6). <https://doi.org/10.1152/ajpendo.00028.2007>
- Jones, C. M., & Boelaert, K. (2015). The Endocrinology of Ageing: A Mini-Review. *Gerontology*, 61(4), 291–300. <https://doi.org/10.1159/000367692>
- Khalil, F., Elassal, M., Hussein, A., Rizk, M., Awadein, M., Behiry, E., & Abd El-Fadil Kelany, M. (2017). Serum prolactin level as a biological marker of severity in liver cirrhosis. *Benha Medical Journal*, 34(2), 140. https://doi.org/10.4103/bmfj.bmfj_60_17
- La Torre, D., & Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. *Therapeutics and Clinical Risk Management*, 3(5), 929–951. <https://doi.org/10.1055/s-2008-1067944>
- Lau, C., & Aw, T. (2019). A Current Approach to Hyperprolactinemia. *International Archives of Endocrinology Clinical Research*, 5(1). <https://doi.org/10.23937/2572-407x.1510018>
- Lee, M.-S., Song, H.-C., An, H., Yang, J., Ko, Y.-H., Jung, I.-K., & Joe, S.-H. (2010). Lee 2010 - Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia.pdf. In *Psychiatry and Clinical Neurosciences* (Vol. 64, pp. 19–27).
- Liu, X., Tang, C., Wen, G., Zhong, C., Yang, J., Zhu, J., & Ma, C. (2019). The mechanism and pathways of dopamine and dopamine agonists in prolactinomas. In *Frontiers in Endocrinology* (Vol. 10, Issue JAN). Frontiers Media S.A. <https://doi.org/10.3389/fendo.2018.00768>
- Mahmood, I. H., Al-Husaynei, A. J., & Mohamad, S. H. (2010). Comparative effects of bromocriptine and cabergoline on serum prolactin levels, liver and kidney function tests in hyperprolactinemic women. *Pakistan Journal of Medical Sciences*, 26(2), 255–260.
- Majumdar, A., & Mangal, N. S. (2013). Hyperprolactinemia. *Journal of Human Reproductive Sciences*, 6(3), 168–175. <https://doi.org/10.4103/0974-1208.121400>
- McCallum, R. W., Sowers, J. R., Hershman, J. M., & Sturdevant, R. A. L. (1976). Metoclopramide stimulates prolactin secretion in man. *Journal of Clinical Endocrinology and Metabolism*, 42(6), 1148–1152. <https://doi.org/10.1210/jcem-42-6-1148>
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011). Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical practice guideline. In *Journal of Clinical Endocrinology and Metabolism* (Vol. 96, Issue 2, pp. 273–288). <https://doi.org/10.1210/jc.2010-1692>
- Moisi, M., Cruz, A., Benkers, T. L., Rostad, S., Broyles, F., Mayberg, M. R., & Yuen, K. C. J. (2017). Treatment of aggressive prolactinsecreting pituitary adenomas with adjuvant temozolomide chemotherapy. In *The Art of*

- Neuroendocrinology: A Case-Based Approach to Medical Decision-Making* (pp. 235–245). Nova Science Publishers, Inc. <https://doi.org/10.7759/cureus.658>
- Molitch, M. E. (2005). Medication-induced hyperprolactinemia. *Mayo Clinic Proceedings*, 80(8), 1050–1057. <https://doi.org/10.4065/80.8.1050>
- Molitch, M. E. (2008). Drugs and prolactin. *Pituitary*, 11(2), 209–218. <https://doi.org/10.1007/s11102-008-0106-6>
- Nielsen-Kudsk, J. E., & Bartels, P. D. (1990). Lack of effect of verapamil on diurnal and thyrotropin releasing hormone stimulated thyrotropin levels in man. *Thyroidology / A.P.R.I.M.*, 2(1), 13–16.
- Omolola. (2023). Bromocriptine Mechanism of Action Action Pathway. In *Pathwhiz*. https://smpdb.ca/pathwhiz/pathways?last_images=true&limit=10&page=11329&sort_by=pw_id&sort_order=asc&subject=disease
- Ozery, M., & Wadhwa, R. (2023). *Bromocriptine*. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. <https://www.ncbi.nlm.nih.gov/books/NBK555948/>
- Parra, A., Alarcon, J., Gavino, F., Ramirez, A., & De los Monteros, A. E. (1993). Age-related changes in the metoclopramide-induced prolactin release in nulliparous women. *Fertility and Sterility*, 60(1), 34–39. [https://doi.org/10.1016/S0015-0282\(16\)56032-4](https://doi.org/10.1016/S0015-0282(16)56032-4)
- Polleri, A., Masturzo, P., Murialdo, G., & Agnoli, A. (1981). Circadian rhythmicity of prolactin secretion in elderly subjects: changes during bromocriptine treatment. *Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology*, 4(3), 317–321. <https://doi.org/10.1007/BF03349450>
- Rabinovich, I. H., Gómez, R. C., Mouriz, M. G., & García-Agulló, D. O. (2013). Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. *Endocrinología y Nutrición (English Edition)*, 60(6), 308–319. <https://doi.org/10.1016/j.endoen.2012.11.009>
- Rasmussen, C., Bergh, T., Nillius, S. J., & Wide, L. (1985). Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. *Fertility and Sterility*, 44(1), 31–34. [https://doi.org/10.1016/s0015-0282\(16\)48673-5](https://doi.org/10.1016/s0015-0282(16)48673-5)
- Raymond, P., Klein, M., Cuny, T., Klein, O., Salleron, J., & Bernier-Chastagner, V. (2021). High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas. *BMC Cancer*, 21(1). <https://doi.org/10.1186/s12885-021-09045-3>
- Rezk, A. Y., Abd El- Hameed, A. A., Assar, T. M., & Abbas, A. K. (2020). Comparison between Rectal Bromocriptine and Oral Cabergoline in Treatment of Hyperprolactinemia. *Benha Journal of Applied Sciences*, 5(8), 185–194. <https://doi.org/10.21608/bjas.2020.187188>
- Sabuncu, T., Arikian, E., Tasan, E., & Hatemi, H. (2001). Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. *Internal Medicine*, 40(9), 857–861. <https://doi.org/10.2169/internalmedicine.40.857>
- Saleem, M., Martin, H., & Coates, P. (2018). Prolactin biology and laboratory

- measurement: An update on physiology and current analytical issues. *Clinical Biochemist Reviews*, 39(1), 3–16.
- Samperi, I., Lithgow, K., & Karavitaki, N. (2019). Hyperprolactinaemia. *Journal of Clinical Medicine*, 8(12), 1–24. <https://doi.org/10.3390/jcm8122203>
- Sawin, C. T., Carlson, H. E., Geller, A., Castelli, W. P., & Bacharach, P. (1989). In the Public Domain Serum Prolactin and Aging: Basal Values and Changes With Estrogen Use and Hypothyroidism. In *Journal of Ceronlologx: MEDICAL SCIENCES*. <http://geronj.oxfordjournals.org/>
- Serri, O., Chik, C. L., Ur, E., & Ezzat, S. (2003). Diagnosis and management of hyperprolactinemia. *CMAJ. Canadian Medical Association Journal*, 169(6), 575–581. <https://doi.org/10.1097/01.pgo.0000873448.25270.f8>
- Souteiro, P., & Karavitaki, N. (2020). Dopamine agonist resistant prolactinomas: any alternative medical treatment? In *Pituitary* (Vol. 23, Issue 1, pp. 27–37). Springer. <https://doi.org/10.1007/s11102-019-00987-3>
- Steiner, J., Cassar, J., Mashiter, K., Dawes, I., Fraser, T. R., & Breckenridge, A. (1976). Effects of methyldopa on growth hormone. *British Medical Journal*, 2(6027), 110. <https://doi.org/10.1136/bmj.2.6027.110-a>
- Tanner, M. J., Hadlow, N. C., & Wardrop, R. (2011). Variation of female prolactin levels with menopausal status and phase of menstrual cycle. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 51(4), 321–324. <https://doi.org/10.1111/j.1479-828X.2011.01321.x>
- Verhelst, J., & Abs, R. (2003). *Hyperprolactinemia: Pathophysiology and Management. Treatments in endocrinology*. <https://doi.org/10.2165/00024677-200302010-00003>
- Vilar, L., Vilar, C. F., Lyra, R., & Da Conceição Freitas, M. (2019). Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. *Neuroendocrinology*, 109(1), 7–19. <https://doi.org/10.1159/000499694>
- Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994). A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. *The New England Journal of Medicine*, 311(14), 904–909. <https://doi.org/https://doi.org/10.1056/NEJM199410063311403>
- Weizman, A., Weizman, R., Ijsenbeek, H., David, M. Ben, & Hart, J. (1983). The Correlation of Increased Serum Desire and Activity in Elderly Men. *Journal of The American Geriatrics Society*, 31, 485–488. <https://doi.org/https://doi.org/10.1111/j.1532-5415.1983.tb05123.x>
- Zaidi, H. A., Cote, D. J., Castlen, J. P., Burke, W. T., Liu, Y. H., Smith, T. R., & Laws, E. R. (2017). Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. *World Neurosurgery*, 97, 2–7. <https://doi.org/10.1016/j.wneu.2016.09.066>